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Oxytocin receptor antagonists 
as a novel pharmacological agent 
for reducing smooth muscle tone 
in the human prostate
Sophie N. Lee1, Jenna Kraska1,3, Melissa Papargiris1,3, Linda Teng1, Birunthi Niranjan1, 
Johanna Hammar2, Andrew Ryan3, Mark Frydenberg4,5, Nathan Lawrentschuk6,7, 
Ralf Middendorff8, Stuart J. Ellem9, Michael Whittaker10, Gail P. Risbridger1 & 
Betty Exintaris2* 
Pharmacotherapies for the treatment of Benign Prostatic Hyperplasia (BPH) are targeted at reducing 
cellular proliferation (static component) or reducing smooth muscle tone (dynamic component), but 
response is unpredictable and many patients fail to respond. An impediment to identifying novel 
pharmacotherapies is the incomplete understanding of paracrine signalling. Oxytocin has been 
highlighted as a potential paracrine mediator of BPH. To better understand oxytocin signalling, 
we investigated the effects of exogenous oxytocin on both stromal cell proliferation, and inherent 
spontaneous prostate contractions using primary models derived from human prostate tissue. We 
show that the Oxytocin Receptor (OXTR) is widely expressed in the human prostate, and co-localises 
to contractile cells within the prostate stroma. Exogenous oxytocin did not modulate prostatic 
fibroblast proliferation, but did significantly (p < 0.05) upregulate the frequency of spontaneous 
contractions in prostate tissue, indicating a role in generating smooth muscle tone. Application of 
atosiban, an OXTR antagonist, significantly (p < 0.05) reduced spontaneous contractions. Individual 
tissue responsiveness to both exogenous oxytocin  (R2 = 0.697, p < 0.01) and atosiban  (R2 = 0.472, 
p < 0.05) was greater in tissue collected from older men. Overall, our data suggest that oxytocin 
is a key regulator of inherent spontaneous prostate contractions, and targeting of the OXTR and 
associated downstream signalling is an attractive prospect in the development of novel BPH 
pharmacotherapies.
Benign Prostatic Hyperplasia (BPH) is an extremely common disorder of the ageing male population, result-
ing from dysregulated proliferation and hypertrophy of the prostate  stroma1. The resultant increase in pressure 
surrounding the urethra contributes to the formation of Lower Urinary Tract Symptoms (LUTS), which have a 
significant burden both in cost and quality of life (QoL) in elderly  men2.
Current pharmacological treatments for BPH aim to either block epithelial/stromal proliferation and inhibit 
cell survival (5α-reductase inhibitors), or prohibit prostatic contractions and reduce prostatic smooth muscle tone 
(α1-adrenoreceptor antagonists (α-blockers); Phosphodiesterase Type 5 (PDE5) inhibitors)3. Both 5α-reductase 
inhibitors and α-blockers are known to be clinically effective at reducing LUTS symptoms, however they both 
have significant impacts independently on  ejaculation4. In combination, men are threefold more likely to develop 
an ejaculatory issue following pharmacological  treatment4. While PDE5 inhibitors have extremely positive effects 
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on  ejaculation5, responsiveness to PDE5 inhibitors is unpredictable, and highly dependent on patient parameters, 
including age, body mass index, and symptom severity prior to commencing  therapy6. As erectile dysfunction 
is a key component of QoL, and is known to significantly contribute to anxiety and depression in older  men7, 
there is an onus on developing new and novel therapies for the treatment of BPH that do not negatively impact 
erectile function.
A possible novel paracrine target for pharmaceutical treatment of BPH is the hormone oxytocin. Oxytocin is 
well described in the female reproductive system for its role in the uterus and pregnancy, where oxytocin induces 
myometrial contractions through its G-protein coupled receptor, the oxytocin receptor (OXTR). Activation of 
the OXTR in the uterus through the Gαq/11-subunit leads to the downstream activation the IP3/DAG signal-
ling pathway, leading to smooth muscle  contraction8. Previous studies have indicated that glandular regions of 
the prostate are immunoreactive for oxytocin, with staining for OXTR observed in both glandular and stromal 
regions of the  prostate9,10. Herbert et al. reported that the expression of the OXTR increased with age and was 
higher in the BPH  tissue11. There is some evidence that oxytocin induces contraction within the human prostate. 
A number of studies report oxytocin inducing contraction of human, guinea pig and dog prostate  tissue12,13. How-
ever, a study conducted by Gupta et al. failed to induce contraction of the rat prostate in response to  oxytocin14, 
raising the question of differing responses between species of mammal.
Other G-protein subunits of the OXTR are linked to both proliferative and anti-proliferative pathways in 
different  organs15. The role of oxytocin on prostate proliferation has yet to be fully elucidated, with conflicting 
reports that oxytocin is able to regulate proliferation of stromal and epithelial  cells10,16. Whittington et al. demon-
strated that incubation of isolated primary prostate fibroblasts with oxytocin significantly reduced  proliferation16, 
while, in contrast, Xu et al.  showed that incubation of immortalised prostate fibroblasts (WPMY-1) increased 
proliferation via activation of the MAP/ERK  pathway10.
To clarify the role of oxytocin within the prostate, we utilised a cohort of human primary prostate speci-
mens to investigate the effects of exogenous oxytocin on both the proliferation and contractility of the prostate, 
and examine the suitability of atosiban, a commonly clinically utilised OXTR antagonist, as a potential BPH 
pharmacotherapy.
Materials and methods
Patient cohort. Human prostatic tissue was collected with informed written consent from patients and 
approval from the Cabrini Human Research Ethics Committee (13-14-04-08), Epworth HealthCare Human 
Ethics Committee (53611) and Monash University Human Research Ethics Committee (2004/145). All experi-
ments were performed in accordance with relevant guidelines and regulations. Tissue was collected from men 
undergoing radical prostatectomy for the treatment of low to medium grade prostatic cancer (Gleason Grade 
Group ≤ 3), with patient data listed in Table 1.
Tissue procurement. Patients were selected prior to surgery based on biopsy results, indicating a low-
grade, small volume tumour localised to the Peripheral Zone (PZ) of the prostate. Tissue was collected exclu-
sively from the Transition Zone (TZ) of the prostate, as this is the area most proximal to the urethra, and the 
zone from which BPH arises. Dissection of non-malignant tissue from the prostate was performed by a board-
certified pathologist, with Haematoxylin and Eosin (H&E) staining performed on a small piece of adjacent tissue 
to ensure no tumour infiltration within the non-malignant section. Tissue for histology was placed in formalin 
(10%), with tissue for organ bath and cell cultures placed in Physiological Saline Solution (PSS; 2.5 mM  CaCl2, 
11 mM d-Glucose, 5 mM KCl, 120 mM NaCl, 25 mM  NaHCO3, 1.2 mM  KH2PO4, 1.2 mM  MgSO4, bubbled 
with a 95%  O2:5%  CO2 gas mixture to maintain a pH of 7.3–7.4), and transfer media [RPMI 1640 with penicil-
lin–streptomycin (P–S), 5% Fetal Calf Serum (FCS), and gentamicin (100 µg/mL)] respectively.
Immunohistochemistry and tissue stains. Sections were de-paraffinised and rehydrated through a 
series of xylene and graded ethanol solutions. Sections were placed in 1.2%  H2O2 for 15 min to block endog-
enous peroxidase activity. For immunohistochemistry, tissue was incubated with the primary antibody OXTR 
(1 μg/mL; Abcam Cat# ab87312, RRID:AB_10674457), diluted in PBS with 0.2% BSA and 0.1% sodium azide for 
24 h at 4 °C. Sections were washed with PBS, and incubated with an anti-goat secondary antibody (1.25 μg/mL), 
the Vectastain ABC-HRP Kit and DAB + chromogen (DAKO), followed by counterstaining with haematoxy-
Table 1.  Patient demographics.
Demographic Number (% of cohort) Mean (± SD) Range
Total patients 15 (100)
Clinical BPH diagnosis 0 (0)
Minimal LUTS reported 4 (26.67)
Significant LUTS reported 0 (0)
Age 67.7 (6.97) 53–75
Prostate volume (cc) 39.46 (9.09) 27–55
Gleason score 7 (N/A) 6–9
Percent tumour volume (tumour volume/total volume) 6.99 (4.06) 1.53–15
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lin. For immunofluorescence, sections were incubated with both α-Smooth Muscle Actin (α-SMA) (5.3 μg/mL, 
Sigma-Aldrich Cat# A2547, RRID:AB_476701) and OXTR, and visualised using a donkey anti mouse IgG Alexa 
Fluor 488 secondary antibody (1:500, Molecular Probes Cat# A-21202, RRID:AB_141607), and a rabbit anti goat 
IgG Alexa Fluor 555 secondary antibody (1:500, Thermo Fisher Scientific Cat# A-21428, RRID:AB_2535849). 
Sections were incubated with DAPI (1:1000, Thermo Fisher Scientific Cat# D3571, RRID:AB_2307445). Nega-
tive control staining was performed by incubating sections with Goat IgG (Zymed Laboratories 02-6202) and/
or Mouse IgG2a (Dako X094301-2).
Organ bath studies. Tension recordings were obtained from transition zone (TZ) specimens as previously 
 described17.
An initial tension of 25 mN was applied to the tissue, which was then left to equilibrate for 60 min. The ‘basal 
tension’ describes the tension of the tissue following this equilibration period. This tension was not re-adjusted 
to a predefined baseline to allow spontaneous contractions to emerge.
Reagent preparation. Powdered oxytocin (Sigma Aldrich, St Louis, MO, USA) and atosiban (Sigma Aldrich, 
St Louis, MO, USA) were dissolved in distilled water to form a 1 mM stock concentration. Serial dilutions were 
performed by diluting the 1 mM stock into PSS solution.
Concentration–response curve to oxytocin. Following the equilibration period, a cumulative concentration–
response curve (CDC) to oxytocin (0.1 nM to 10 μM) were constructed by perfusing sections for four (4) min-
utes with increasing concentrations of oxytocin dissolved in PSS. Following a washout period, the tissue was 
challenged with a potassium chloride solution (20 mM) to assess tissue viability and reliably induce a robust 
contraction in all viable preparations. Preparations were subsequently weighed following the completion of 
experiments.
Spontaneous contractions. Following the equilibration period, the preparation was incubated with increasing 
concentrations of atosiban (1, 10, 100, and 300 nM) prepared in fresh Physiological Saline Solution (PSS), for 
a period of 10 min at each concentration. Following a washout period, the tissue was challenged with a potas-
sium chloride solution (20 mM) to assess tissue viability. Preparations were weighed following the completion 
of experiments, with the amplitude of spontaneous contractions (Δ change in tension from baseline) normalised 
to tissue  weight18.
Analysis of contractile recordings. Analysis of tension recordings focused on three parameters: basal tension 
(the inherent tension within the tissue; mN), as well as amplitude and frequency (strength and speed of contrac-
tions; N/g and  min−1, respectively) as previously  reported19,20. These parameters are as used in previous studies 
to define spontaneous  contractions19,21,22. Chart Pro v 5.5.6 was used to analyse the tension recordings, with 
indicated parameters measured for 5 consecutive responses and averaged before (control), and for each concen-
tration of drug.
Cell culture. Primary patient derived fibroblasts were isolated from prostate tissue using an established 
methodology described by Lawrence et al.23. Briefly, tissue was collected using the above methodology, placed 
in transfer media, and weighed. Tissue was washed in PBS supplemented with gentamicin (100 µg/mL), and cut 
into ~ 1  mm2 pieces using sterile scalpel blades. The dissected tissue was placed into RPMI1640 media containing 
P–S, 5% FCS, gentamicin, 225 U/mL collagenase and 125 U mL hyaluronidase and incubated in an oven (37 °C) 
with a rotator for 16 h (overnight). Following incubation, the tissue was processed into a single cell suspension by 
mechanical digestion with pipette tips, and centrifuged. The remaining cell pellet was resuspended in RPMI1640 
media containing 5% FCS and P–S antibiotics and placed in a T25 flask. Following initial passage, cells were 
cultured in RPMI/5% FCS/1 nM testosterone/P–S and utilised at passages 4–8. WPMY-1 immortalised prostate 
fibroblasts were obtained as a gift from Professor Judith Clements and were utilised at passages 49–52.
Reagent preparation. Powdered oxytocin (Sigma Aldrich, St Louis, MO, USA) and atosiban (Sigma Aldrich, 
St Louis, MO, USA) were dissolved in distilled water to form a 1 mM stock concentration. Serial dilutions were 
performed in culture media (RMPI 1640 without Phenol Red, with 5% charcoal stripped FCS and P–S antibiot-
ics) to ensure the final volume of reagent dissolved in distilled water added to each well was the equivalent of 
0.01% total media volume. Distilled water was added at the equivalent volume of 0.01% media volume to control 
columns to act as a vehicle control.
Proliferation. Fibroblast proliferation in response to oxytocin [0.1 nM–1 µM] was determined using Cell Titre 
96 Aqueous One assays (Promega, Australia). Cells were seeded into a 96 well plate at a cell density of 5 ×  103, and 
media changed to RMPI 1640 without Phenol Red, with 5% charcoal stripped FCS and P–S antibiotics to remove 
any proliferative effects mediated by steroid hormones. Media was changed every two (2) days for the course of 
the experiment. Proliferation was measured at 72 h and 120 h following initial treatment of the cells with oxy-
tocin, with additional oxytocin of the same concentration and volume of reagent added to the media every 24 h. 
Atosiban (0.1 nM–1 μM) was added to media, with proliferation assessed after 72 h. Cells were incubated for one 
(1) hour with assay reagents, following which absorbance was measured at 490 nM, using a FLUOstar Optima 
plate reader (BMG, Germany). Three (n = 3) independent experiments were performed per cell line, with each 
experiment containing three (3) technical replicates.
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RNA analysis. RNA was collected from cells treated with the vehicle control (0.01% distilled water), 1 nM, 
10 nM and 100 nM of Oxytocin for 72 and 120 h, with additional oxytocin of the same concentration and vol-
ume of reagent added to the media every 24 h of culture. RNA was extracted using TRIzol (Invitrogen), DNase-
treated and cDNA generated using Superscript III (Roche, Switzerland).
Qualitative RT‑PCR. Qualitative real time PCR (qRT-PCR) was performed using cDNA generated as described 
above. Primers utilised in this experiment are listed in Table 2. PCR analysis was performed using QuantiTect 
SYBR Green Kit (Qiagen). Each gene was normalised to the housekeeping gene (GAPDH) and compared with 
vehicle controls using the  2−ΔΔCt method, and fold change was calculated relative to vehicle control of independ-
ent cell lines.
Statistical analysis. The half-maximal  (EC50) value was calculated using GraphPad Prism version 7.05 for 
Windows (GraphPad Software, La Jolla California USA). Unless noted, all data are mean ± SEM, with statistical 
analysis performed by Student’s t-test, one-way ANOVA and Dunnets post hoc test, or two-way ANOVA and 
Tukeys post hoc test, using GraphPad Prism version 7.05 software with significance deemed at p < 0.05. A gen-
eralized Extreme Studentized Deviate (ESD) test with an Alpha level of 0.05 was performed to exclude outliers. 
Multi-linear regression analysis was used to correlate clinical records with the percentage response to pharmaco-
therapy treatment using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp: Armonk, NY).
Results
Oxytocin receptor is widely expressed in the human prostate, and is co-localised with con-
tractile cells in the prostate stroma. Immunohistochemistry was conducted to assess the presence and 
distribution of OXTR. Specificity of staining was determined by substituting the primary OXTR antibody for 
goat immunoglobulin, diluted to 1.25 μg/mL (Fig. 1A, I). OXTR expression was observed in both epithelial and 
stromal cells (Fig. 1A, II & II). The epithelial compartment demonstrated consistent staining for the OXTR in all 
visible glands (observed by brown DAB staining), with no noticeable difference observed visually in the staining 
of basal or luminal cells. To determine if OXTR was expressed on contractile cells, double immunofluorescence 
staining was performed for OXTR and α-Smooth Muscle Actin (α-SMA), a well-established cytoskeleton protein 
of contractile cells. Co-localization between OXTR and α-SMA was observed (Fig. 1B).
Oxytocin did not modulate the proliferation of prostatic stromal cells, but upregulated the 
mRNA expression of OXTR and genes related to smooth muscle differentiation. To assess 
the effect of exogenous oxytocin on the static component of BPH, an immortalised and two primary derived 
prostate fibroblasts were exposed to oxytocin at increasing concentrations [0.1 nM–1 μM]. Proliferation was 
assessed using a commercially available proliferation assay 72 or 120 h following initial exposure to oxytocin, 
and proliferation normalised to the vehicle control (% control proliferation). There was no significant difference 
in proliferation at any concentration of oxytocin (Fig. 2A, I & II). Primary patient derived fibroblasts (NPF1 & 
NPF2) were additionally exposed to atosiban [0.1 nM–1 μM], an OXTR antagonist for 72 h, with no significant 
changes in proliferation observed (Fig. 2A, III). Proliferation was significantly increased from vehicle control 
in NPF2 cells treated with oxytocin [1 μM] and atosiban [300 nM] simultaneously, although this result was not 
replicated with NPF1 cells, or at lower concentrations of oxytocin (Fig. 2A, IV).
RNA was harvested from cells at the same time point, and qualitative RT-PCR was used to assess the fold 
change of the genes SMTN, CNNI1, ACTA2, COL1A and FN1 in cells exposed to oxytocin [10 nM] for 72 h. 
SMTN and CNN1 encode the genes smoothelin and calponin, markers of prostate smooth muscle differentia-
tion, and both were upregulated ~ twofold in primary patient derived fibroblasts, but not in the immortalised 
line (Fig. 2B). ACTA2 encodes α-SMA, which is a marker of both myofibroblast and smooth muscle differentia-
tion and was ~ 2–2.5 fold upregulated in all cell lines. The fibroblast markers COL1A, which encodes Collagen 
I, was elevated by 1.8-fold in the WPMY-1 cell line, but not in the two patient derived fibroblasts. FN1, which 
Table 2.  PCR primer sequences.
Gene Primer sequence Product length (base pairs)
SMTN (fwd) 5′-GAG CAG ACC CGA GTG AAC AA-3′(rev) 5′-CGT GCT CTG ATC CAG CAT CT-3′ 111
CNN1 (fwd) 5′-TCC AGC CCC TGT AGA ACT CA-3′(rvs) 5′-GAA TAG CGT TGC TCA GTG CG-3′ 168
ACTA2 (fwd) 5′-TGT AAG GCC GGC TTT GCT -3′(rvs) 5′-CGT AGC TGT CTT TTT GTC CCATT-3′ 112
COL1A1 (fwd) 5′-GGG TAA GTC CCT TTC TGC CC-3′(rvs) 5′-TTG GGT GTT TGA GCA TTG CC-3′ 177
FN1 (fwd) 5′-ACA AGC ATG TCT CTC TGC CAA-3′(rvs) 5′-GCA ATG TGC AGC CCT CAT TT-3′ 192
OXTR (fwd) 5′-GAC TCG GTG CAG TGG AAG C-3′(rvs) 5′-CTC CTC TGA GCC ACT GCA AA-3′ 108
GAPDH (fwd) 5′GCA AAT TCC ATG GCA CCG T-3′(rvs) 5′-TCG CCC CAC TTG ATT TTG G-3′ 106
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encodes Fibronectin, was not upregulated in any cell line following exposure to oxytocin (Fig. 2B). Exposure 
to oxytocin [10 nM] induced a ~ two- to three-fold increase in mRNA transcripts of the OXTR gene across all 
three cell lines (Fig. 2C).
Oxytocin induced an increase in the frequency of spontaneous contractions of the human 
prostate. To assess the effect of exogenous oxytocin on the dynamic component of BPH, primary human 
prostate tissue was collected from the Transition Zone (TZ) of men undergoing radical prostatectomy, and con-
tractility was assessed in vitro using organ bath techniques. Specimens were exposed to cumulative concentra-
tions of exogenous oxytocin [0.1 nM–10 μM] (Fig. 3A, I), with the average basal tension (mN), amplitude (N/g) 
and frequency  (min−1) of spontaneous contractions assessed, and converted to a percentage of control spontane-
ous activity (Fig. 3B, I, II & III respectively). Tissue viability was assessed following a washout period after the 
completion of the dose–response curve by exposing tissue to potassium chloride (KCl; 20 mM), which induced a 
robust contraction in all preparations (Fig. 2B). Oxytocin did not significantly modulate basal tension or ampli-
tude, but did significantly (p < 0.05) upregulate the frequency of spontaneous contractions.
Interpatient variability in the increase in frequency of spontaneous contractions was corre-
lated with age. The half maximal  (EC50) of exogenous oxytocin was determined by non-linear regression to 
occur at 233.1 nM (Fig. 4A). However, there was a notable interpatient variability in the percentage change from 
baseline frequency. Linear regression analysis was performed against percentage change from baseline frequency 
at 1 μM, and patient clinical parameters. A significant association was observed between percentage change and 
patient age at time of radical prostatectomy (Fig. 4B). Division of the cohort into groups under (n = 3) and over 
(n = 6) 60 years of age indicated that older patient tissue had a significant (p < 0.05) increase in the frequency of 
spontaneous contractions (Fig. 4C, I), and this was not observed in tissue from men under 60 years old (Fig. 4C, 
II).
Atosiban significantly attenuated spontaneous contractile parameters. To determine its poten-
tial as a BPH pharmacotherapy, unstimulated sections of human prostate were incubated with increasing con-
centrations of atosiban, an OXTR antagonist [1, 10, 100 and 300 nM]. Sections had not been exposed to any 
exogenous stimulus prior to incubation with atosiban. The basal tension of spontaneous contractions was sig-
nificantly (p < 0.05) reduced at 100 nM and 300 nM (Fig. 5B, I), with amplitude and frequency (Fig. 5B, II & III 
respectively) also significantly attenuated at 300 nM of atosiban (p < 0.05).
Interpatient variability in the decrease in the frequency of spontaneous contractions was cor-
related with age. Regression analysis was performed against the percentage decrease of all three param-
eters at atosiban [300 nM] and patient age. A significant  (R2 = 0.472, p < 0.05) association was observed between 
percentage change from baseline frequency and age, indicating tissue from older patients had a greater reduction 
Figure 1.  The oxytocin receptor is widely expressed in the human prostate and is co-localised with contractile 
stromal cells. Representative images of sections of human prostatic transition zone specimens with (A) 
immunohistochemistry staining of (I) negative control (scale bar = 200 μm), and (II, III) oxytocin receptor 
(OXTR) (scale bar = 200 μm and 100 μm respectively), and (B) Immunofluorescence staining of DAPI, 
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in the frequency of spontaneous contractions (Fig. 5C, III). No association was observed between age and per-
centage change from baseline basal tension or amplitude (Fig. 5C, I & II respectively).
Discussion
Our study investigated the role of the peptide hormone oxytocin in prostate physiology, and is the first study 
to comprehensively describe the effects of oxytocin and Atosiban on spontaneous contractility of the human 
prostate. While no significant effects of oxytocin on proliferation of stromal cells was observed, treatment of pri-
mary prostatic fibroblasts expressing the OXTR upregulated mRNA transcripts of genes associated with smooth 
muscle differentiation. These results support the intriguing possibility of OXTR antagonists as a pharmaceutical 
agent for the treatment of BPH.
We have previously demonstrated that the frequency of myogenic contractions are significantly upregulated 
in men with clinically diagnosed  BPH17, and hypothesised that changes to inherent myogenic contractility are 
driven by intrinsic factors within the prostate, notably oxytocin levels. The presence of the OXTR in the human 
prostate was previously  described9 and confirmed in this study (Fig. 1). Dual staining immunofluorescence 
revealed co-localization of OXTR with α-SMA (a marker of contractile filaments), supporting our hypothesis 
Figure 2.  Exogenous oxytocin did not induce proliferation of stromal cells in culture. (A) To assess the static 
component, isolated primary patient derived non-malignant (NPF1 and NPF2) and immortalised (WMPY1) 
human prostate fibroblasts were exposed to (I) exogenous oxytocin (0.1 nM–1 μM) for 72 h, exogenous oxytocin 
(0.1 nM–1 μM) for 120 h (III) the OXTR antagonist Atosiban (0.1 nM–1 μM), or (IV) increasing concentrations 
of exogenous oxytocin (0.1 nM–1 μM), in the presence of Atosiban (300 nM) in culture for 72 h, following 
which proliferation was assessed using Cell Titre 96 Aqueous One cellular proliferation assay, with proliferation 
normalised to the vehicle control of each cell line (n = 3), unpaired one-way ANOVA with Dunnet’s multiple 
comparisons test, ***p ≤ 0.001). (B) RNA was harvested from cells treated with Oxytocin (10 nM) for 72 h and 
qualitative RT-PCR was used to determine the fold change in mRNA transcripts from vehicle control for genes 
involved in myofibroblast differentiation. (III) fold change in Oxytocin Receptor (OXTR) mRNA transcript 
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that oxytocin is a modulator of contractility within the prostate. Herbert et al., previously reported weak OXTR 
staining in younger men (9 and 18 years old), which increased with age (28 and 33 years old) and in BPH patients. 
However, they did not comment about which compartment (epithelial or stromal) the intensity of staining was 
increased in, rather they reported an overall  increase11. A future direction would be to identify specifically which 
compartment of the prostate OXTR expression increases in with age, as we were unable to address this due to 
our cohort of older patients (> 53 years old).
The application of exogenous oxytocin significantly increased the frequency of spontaneous contractions 
in a dose-dependent manner. Assinder and Nicholson determined that explants of human prostate produced 
endogenous  oxytocin24, suggesting that oxytocin is a paracrine regulator of spontaneous smooth muscle tone 
in the human prostate. Significantly, we also demonstrate that application of atosiban, an OXTR antagonist, 
reduced the basal tension, amplitude, and frequency of spontaneous contractions by 9.52 ± 1.42%, 34.7 ± 6.9% and 
34.9 ± 7.8% respectively at a concentration of 300 nM. Atosiban was applied to unstimulated sections of human 
prostate, supporting the hypothesis that oxytocin endogenously contributes to prostatic smooth muscle tone.
Correlation analysis between changes in the frequency of spontaneous contractions in response to both 
oxytocin and atosiban indicate that tissue collected from older men had greater responsiveness compared to 
younger men within the cohort. As the percentage of men suffering from BPH significantly increases with  age2, 
a pharmaceutical agent that is more effective in older men is of clinical interest. We postulate the age-related 
differences found within our studies are likely a reflection of changes in the expression of the OXTR within the 
transition zone of the human prostate. Our results are consistent with an earlier publication by Herbert et al., 
which noted an increased distribution of OXTR in human prostate tissue collected from older men, compared 
to younger  controls11. We hypothesise this mechanism is likely to occur as a result of the changing hormonal 
balance within the prostate as men age, with testosterone levels decreasing while estrogen levels remain  steady25. 
In the uterus, increasing estrogen concentrations are associated with an upregulation in OXTR  expression26. 
However, further studies are needed to determine if estrogen induces OXTR upregulation in the human pros-
tate. A future avenue to investigate this would be to examine the expression of OXTR and responsiveness of 
prostate tissue to oxytocin from men treated with 5α-reductase inhibitors, as this treatment alters the hormone 
balance within the prostate, and may interact and alter oxytocin signalling. Another possible mechanism is 
that increased oxytocin may regulate changes in expression of the OXTR. In isolated stromal cells, exposure 
to 10 nM of exogenous oxytocin increased mRNA expression of the OXTR by ~ two- to three-fold after 72 h in 
culture. Therefore, increasing levels of oxytocin may positively regulate the expression of the OXTR, leading to 
increased sensitivity in older men.
Figure 3.  Application of exogenous oxytocin modulated the dynamic component by significantly increasing the 
frequency of spontaneous contractions within the human prostate. To assess the dynamic component, primary 
human prostate tissue collected from the transition zone (TZ) was exposed to increasing concentrations of 
exogenous oxytocin (0.1 nM–10 μM). (A) representative trace of spontaneous contractions following exposure 
to exogenous oxytocin (0.1 nM–10 μM). (B) Application of High KCl (20 mM) induced a robust contraction 
following conclusion of the dose response curve, confirming tissue viability. The percentage change (% change) 
from baseline (I) basal tension, (II) amplitude and (III) frequency of spontaneous contractions following 
application of exogenous oxytocin (0.1 nM–10 μM) (n = 9, paired one-way ANOVA with Dunnets multiple 
comparisons test, *p < 0.05, **p < 0.01).
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Whittington et al. reported that oxytocin reduced the proliferation of primary prostate  fibroblasts16, in con-
trast to Xu et al., who reported that oxytocin induced proliferation of the immortalised cell lines RWPE-1 (pros-
tate epithelium) and WPMY-1 (prostate fibroblasts) through the MAPK/ERK  pathway10. A recent publication 
by Li et al. reported increased proliferation in WPMY-1 cells in response to oxytocin, with significant results 
observed after 5 days treatment with 10 nM of  oxytocin27. Our study did not find a significant impact of oxy-
tocin on fibroblast proliferation. We hypothesise this is likely due to different methodology used between these 
studies, as we replenished media with additional oxytocin every 24 h to account for the short biological half-
life of the hormone and used both primary and immortalised cell lines to compare differences in response. As 
WPMY-1 cells are an immortalized line, we used these cells at a much higher passage (49–52) than our primary 
cell lines (maximum passage number of 8). There is a higher risk of the WPMY-1 cell line undergoing genotypic 
and phenotypic variation over an extended period, and as such may not adequately represent primary  cells28. 
It is unclear at which passage Li et al. obtained the WPMY-1 cell line, hence offering a possible reason for the 
differing results. However, across all three (3) lines, we did not observe any significant differences in the rate of 
proliferation after 72-h of culture.
Fibroblasts and stromal cells play an important role in the initiation and progression of  BPH29. Schauer 
and Rowley propose that BPH arises because of a “reactive stroma”, predominantly caused by  myofibroblasts30. 
Primary stromal cultures isolated from the human prostate contain a mixture of fibroblast, myofibroblasts, and 
smooth muscle cells, which have been demonstrated to differentiate to another phenotype in cell  culture31. In 
the fibroblast lines utilised in this study, all cells express vimentin but show a heterogenous expression of α-SMA, 
indicating a mixed line of fibroblast and myofibroblasts. By treating fibroblasts with 10 nM of exogenous oxytocin, 
we observed an upregulation of markers of myofibroblast differentiation, notably ACTA2, which was ~ 2–2.5 fold 
upregulated at the mRNA level. While the trend between cell lines was different, overall, the data suggests that 
oxytocin induces a change in the genes involved in the differentiation state of stromal cells. The higher endog-
enous levels of oxytocin in the prostate observed by Assinder and Nicholson may promote the differentiation 
from a fibroblast or myofibroblast to a smooth muscle phenotype, augmenting disease progression by promoting 
a reactive stroma. Therefore, lowering endogenous oxytocin may be an important pharmacological target for 
reducing the quantity of reactive stroma and smooth muscle/tone cells within the prostate.
OXTR antagonists are of interest in the treatment of premature ejaculation (PE), and show promising pre-
liminary results in animal  models32. Cligosiban (IX-10) was recently determined by a Phase II, randomised, 
Figure 4.  Variability in oxytocin induced change in spontaneous contraction frequency is significantly 
correlated with age. (A) Dose response curve of % change from baseline frequency with increasing 
concentration of exogenous oxytocin (n = 9, non-linear regression). (B) Correlation between % change from 
baseline frequency and age (n = 9, Linear Regression analysis, p < 0.05 considered significant). (C) % change 
from baseline frequency in response to increasing concentrations of exogenous oxytocin from prostate tissue 
collected from men (I) less than 60 years old (n = 3), and (II) greater than 60 years old (n = 6) (paired one-way 
ANOVA with Dunnets multiple comparisons test, *p < 0.05, **p < 0.01, ***p < 0.001).
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double-blind, placebo-controlled study to be effective in treating  PE33. As PE is a common co-morbidity with 
 BPH34, OXTR antagonists may be of dual benefit in the treatment of both diseases.
A limitation of our study is that we did not investigate the role of epithelial or co-cultured cells in our cell 
culture experiments. However, the focus of our investigation was on the role of oxytocin in the prostate stroma, 
as it is the compartment that most contributes to the pathogenesis of  BPH35. Our cell culture experiments were 
designed to address the contentious findings between previous  publications10,16,27 with regards to the proliferative 
effects of oxytocin on prostate fibroblasts by using a robust methodology and both primary and immortalised 
cell lines. Hence, the focus of our paper was not on the epithelium, although epithelial-stromal crosstalk is an 
interesting avenue to consider further due to the presence of OXTR in both compartments of the prostate.
Both an advantage and a limitation of our study was the use of prostate cancer patients to investigate non-
malignant prostate disease. By selecting for low-grade patients with small tumours, we were able to obtain high 
quality prostate specimens directly from the TZ. Previous attempts to obtain tissue directly from BPH patients 
undergoing Transurethral Resection of the Prostate (TURP) resulted in poor quality, often burnt, samples, which 
were unsuitable for organ bath experiments. The average prostate volume (39.46 cc ± 9.09) in our cohort is greater 
than the definition of an enlarged prostate (30 cc)36, indicating that most of the cohort had an enlarged prostate 
at time of prostatectomy. However, as these men were treated for prostate cancer, we have limited information 
regarding their overall BPH symptomology, such as IPSS scores, urine flow rate, and BMI, which limited the 
correlation analysis we were able to perform to age and prostate volume. As age, prostate volume and BPH 
progression are so intrinsically  linked2, there is a causality dilemma in our findings; while the majority of our 
Figure 5.  Application of atosiban, an OXTR antagonist, significantly reduced spontaneous contractile 
parameters in human prostate specimens, with reduction in frequency correlated with age. (A) Representative 
trace of spontaneous contractions (I) prior to and (II) following application of atosiban [300 nM]. (B) Average % 
change from baseline (I) basal tension, (II) amplitude, and (III) frequency of spontaneous contractions following 
incubation with increasing concentrations of atosiban [1, 10, 100 and 300 nM] (n = 10. paired one-way ANOVA 
with Dunnets multiple comparisons test, *p < 0.05, **p < 0.01). (C) correlation between average % change from 
baseline (I) basal tension, (II) amplitude, and (III) frequency of spontaneous contractions following incubation 
with atosiban [300 nM] with age (n = 10, Linear Regression analysis, p < 0.05 considered significant).
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findings are an assessment of prostate tissue function in the presence of oxytocin and an OXTR, the age and 
prostate enlargement in our cohort means the relevance of our findings to the BPH disease state are significant.
Overall, BPH is a highly prevalent disease of the ageing male population, with limited pharmaceutical inter-
ventions available. Our report highlights the importance of oxytocin as a paracrine regulator of the dynamic 
component of BPH, particularly in upregulating the frequency of spontaneous contractions in the human pros-
tate. This study provides a rationale for further investigation into the use of OXTR antagonists for the clinical 
treatment of BPH.
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